EUVIMEDEUVIMED entdecken
Open Access

Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae

Avrom S Caplan, Gabrielle C Todd, YanChun Zhu, Michelle Sikora, Christine C Akoh, Jeannette Jakus, Shari R Lipner, Kayla Babbush Graber, Karen P Acker, Ayana E Morales, Rebecca M Marrero Rolón, Lars F Westblade und 10 weitere

JAMA Dermatology · 2024

DOI: 10.1001/jamadermatol.2024.1126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, 2024. Verfasst von Avrom S Caplan und 21 weiteren Autor:innen. Beteiligte Einrichtung: The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Hauptthemen laut MEDLINE: Antifungal Agents, Tinea, Trichophyton, Microbial Sensitivity Tests. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Trichophyton indotineae is an emerging dermatophyte causing outbreaks of extensive tinea infections often unresponsive to terbinafine. This species has been detected worldwide and in multiple US states, yet detailed US data on infections with T indotineae are sparse and could improve treatment practices and medical understanding of transmission.

Objective

To correlate clinical features of T indotineae infections with in vitro antifungal susceptibility testing results, squalene epoxidase gene sequence variations, and isolate relatedness using whole-genome sequencing. Design, Setting, and Participants This retrospective cohort study of patients with T indotineae infections in New York City spanned May 2022 to May 2023. Patients with confirmed T indotineae infections were recruited from 6 New York City medical centers. Main Outcome and Measure Improvement or resolution at the last follow-up assessment.

Results

Among 11 patients with T indotineae (6 male and 5 female patients; median [range] age, 39 [10-65] years), 2 were pregnant; 1 had lymphoma; and the remainder were immunocompetent. Nine patients reported previous travel to Bangladesh. All had widespread lesions with variable scale and inflammation, topical antifungal monotherapy failure, and diagnostic delays (range, 3-42 months). Terbinafine treatment failed in 7 patients at standard doses (250 mg daily) for prolonged duration; these patients also had isolates with amino acid substitutions at positions 393 (L393S) or 397 (F397L) in squalene epoxidase that correlated with elevated terbinafine minimum inhibitory concentrations of 0.5 μg/mL or higher. Patients who were treated with fluconazole and griseofulvin improved in 2 of 4 and 2 of 5 instances, respectively, without correlation between outcomes and antifungal minimum inhibitory concentrations. Furthermore, 5 of 7 patients treated with itraconazole cleared or had improvement at the last follow-up, and 2 of 7 were lost to follow-up or stopped treatment. Based on whole-genome sequencing analysis, US isolates formed a cluster distinct from Indian isolates. Conclusion and Relevance The results of this case series suggest that disease severity, diagnostic delays, and lack of response to typically used doses and durations of antifungals for tinea were common in this primarily immunocompetent patient cohort with T indotineae , consistent with published data. Itraconazole was generally effective, and the acquisition of infection was likely in Bangladesh.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsTineaTrichophytonMicrobial Sensitivity TestsHumansMaleFemaleMiddle AgedRetrospective StudiesAdultAgedAdolescentChildYoung AdultWhole Genome SequencingSqualene MonooxygenaseNew York CityTerbinafineDrug Resistance, FungalCohort Studies

Substanzen

Antifungal AgentsSqualene MonooxygenaseTerbinafine

Autor:innen und Institutionen

  • The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.
  • Dermatology Service, Bellevue Hospital Center, New York, New York.
  • Wadsworth Center Mycology Laboratory, New York State Department of Health, Albany.
  • SUNY Downstate Health Sciences University, Department of Dermatology, Brooklyn, New York.
  • Department of Dermatology, Weill Cornell Medicine, New York, New York.
  • Division of Infectious Diseases, Department of Pediatrics, Weill Cornell Medicine, New York, New York.

Zitieren

APA

Caplan, A. S., Todd, G. C., Zhu, Y., Sikora, M., Akoh, C. C., Jakus, J., Lipner, S. R., Graber, K. B., Acker, K. P., Morales, A. E., Rolón, R. M. M., Westblade, L. F., Fonseca, M., Cline, A., Gold, J. A. W., Lockhart, S. R., Smith, D. J., Chiller, T., Greendyke, W. G., …, & Chaturvedi, S. (2024). Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2024.1126

Vancouver

Caplan AS, Todd GC, Zhu Y, Sikora M, Akoh CC, Jakus J, et al. Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae. JAMA Dermatology. 2024. doi:10.1001/jamadermatol.2024.1126

BibTeX
@article{Caplan2024,
  author = {Caplan, Avrom S and Todd, Gabrielle C and Zhu, YanChun and Sikora, Michelle and Akoh, Christine C and Jakus, Jeannette and Lipner, Shari R and Graber, Kayla Babbush and Acker, Karen P and Morales, Ayana E and Rolón, Rebecca M Marrero and Westblade, Lars F and Fonseca, Maira and Cline, Abigail and Gold, Jeremy A W and Lockhart, Shawn R and Smith, Dallas J and Chiller, Tom and Greendyke, William G and Manjari, Swati R and Banavali, Nilesh K and Chaturvedi, Sudha},
  title = {Clinical Course, Antifungal Susceptibility, and Genomic Sequencing of Trichophyton indotineae},
  journal = {JAMA Dermatology},
  year = {2024},
  doi = {10.1001/jamadermatol.2024.1126}
}
Kostenlos starten →